Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On March 23, 2026, Telomir Pharmaceuticals, Inc. shareholders approved amendments to the company’s 2023 Omnibus Incentive Plan, raising the share reserve from 6,500,000 to 11,500,000 and authorizing the administrator to reprice stock options and stock appreciation rights, moves that expand the firm’s flexibility in using equity compensation to incentivize and retain talent. At the same meeting on March 23, 2026, shareholders also approved a bylaw change reducing the quorum requirement for shareholder actions at meetings to one-third, a shift that may make it easier for the company to conduct corporate governance business and secure approvals for future strategic initiatives.
The most recent analyst rating on (TELO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a biopharmaceutical company operating in the pharmaceuticals industry. It focuses on developing drug candidates and related therapies, with its equity-based incentive structures designed to attract and retain employees and executives critical to advancing its pipeline and corporate strategy.
Average Trading Volume: 132,188
Technical Sentiment Signal: Sell
Current Market Cap: $43.32M
Learn more about TELO stock on TipRanks’ Stock Analysis page.